Figure 4.
In the subset of RCTs with data on patients with and without liver metastases, the benefit with VEGFi was more pronounced in patients with liver metastases vs. those without liver metastases for PFS. (A) Forest plot and pooled HRs for PFS in patients with liver metastases (HR = 0.44; 95% CI, 0.33–0.57; high heterogeneity: I2 = 81%, p < 0.001). (B) Forest plot and pooled HRs for PFS in patients without liver metastases (HR = 0.57; 95% CI, 0.45–0.72; high heterogeneity: I2 = 83%, p < 0.001) [18,27,34,35,36,37,40,41,42,45,48,49,50].